Slide mhyosphere vaccine injection for pigs mhyosphere logo THE FIRST INTRADERMAL NEEDLE-FREE VACCINE AGAINST MYCOPLASMA HYOPNEUMONIAE AND PCV2, ALL IN ONE
Mhyosphere vaccine Born to make history

MHYOSPHERE® PCV ID is the first vaccine based on a recombinant Mycoplasma hyopneumoniae strain.

DISCOVER MORE

MHYOSPHERE® PCV ID offers you:

ENZOOTIC PNEUMONIA UNDER CONTROL:

  • Reduction of lung lesions due to Mycoplasma hyopneumoniae and their incidence on farm.
  • With an onset of immunity of 3 weeks after vaccination and a duration of immunity of 23 weeks after vaccination.

BROAD PROTECTION AGAINST PCV2:

  • The first vaccine in Europe with registered efficacy against PCV2 genotypes a, b and d.
  • Reduces viremia, virus load in lungs and lymphoid tissues and the duration of the viraemic period.
  • Reduces virus nasal and faecal shedding and the duration of the viral excretion, from 4 weeks after vaccination.
  • With an onset of immunity of 2 weeks after vaccination and a duration of immunity of 22 weeks after vaccination.

MORE KILOS OF PORK TO THE MARKET:

  • Reduces the culling rate and the loss of daily weight gain, as observed at 6 month of age in field studies, caused by Mycoplasma hyopneumoniae and/or PCV2.

MHYOSPHERE® PCV ID brings effective benefits:

mhyosphere vaccine injection for pigs

READY-TO-USE BENEFITS

Does not require mixing

No risk of contamination from the process.

Saves labour and time.

Fewer injections

Less handling stress so improved animal welfare.

Saves labour and time.

RESULT :

TIME SAVED AND IMPROVED PRODUCTIVITY.

ID BENEFITS

Biosecurity

Reduces the risk of iatrogenic disease transmission between pigs.

Animal Welfare

Less pain and stress, improving animal welfare conditions.

Immune Response

High concentration of dendritic cells in the dermis facilitating a good immune response.

Reduces maternal immunity interference. 1

Food safety and carcass value

Avoids broken needles.

No risk of muscle tissue damage and reduced risk of abscess formation.

RESULT :

ALTERNATIVE TO REDUCE ANTIMICROBIAL USE AND IMPROVE PRODUCTIVITY.

1 L. Sticchi, M. Alberti, C. Alicino, and P. Crovari, “The intradermal vaccination: Past experiences and current perspectives,” J. Prev.Med.Hyg., vol. 51, no. 1, pp. 7–14, 2010.